Robert C. Green, MD, MPH is Professor of Medicine at Harvard Medical School, and directs the Genomes2People Research Program in translational genomics and health outcomes at Brigham and Women’s Hospital and is an Associate Member of the Broad Institute. Originally trained as a neurologist and epidemiologist, he contributed for over a decade to the clinical characterization, treatment trial methodology and risk refinement for Alzheimer’s disease. After re-training as a medical geneticist, he conducts empirical research on the medical, behavioral and economic outcomes around the implementation of genomic medicine. Dr. Green led the first NIH-funded trials disclosing common complex disease risk (REVEAL Study) and the first prospective study of direct-to-consumer genetic testing (PGen Study). He currently leads and co-leads the first randomized trials to explore the implementation of medical sequencing in adults (MedSeq Project) and newborns (BabySeq Project). His team recently published the MedSeq Project results assessing medical outcomes, appropriateness of care and downstream medical costs of whole genome sequencing in primary care. With support from the Air Force, and in collaboration with military medicine colleagues, he is conducting the first implementation study of sequencing with return of results in active duty military personnel (MilSeq Project). Dr. Green was lead author on the original recommendations for managing secondary findings in clinical sequencing from the American College of Medical Genetics and Genomics and led the first published demonstration of aggregate penetrance of genomic variants in an unselected population.